600079 Stock Overview
Researches, develops, produces, and sells pharmaceutical products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Humanwell Healthcare (Group) Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥22.49 |
| 52 Week High | CN¥27.36 |
| 52 Week Low | CN¥15.68 |
| Beta | 0.83 |
| 11 Month Change | 4.36% |
| 3 Month Change | 14.10% |
| 1 Year Change | -5.54% |
| 33 Year Change | 6.69% |
| 5 Year Change | 75.16% |
| Change since IPO | 71.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600079 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -4.3% | -1.5% | -2.1% |
| 1Y | -5.5% | -9.4% | 2.8% |
Return vs Industry: 600079 exceeded the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 600079 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 600079 volatility | |
|---|---|
| 600079 Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 600079 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600079's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 17,676 | Xiafei Deng | www.humanwell.com.cn |
Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection for endotracheal intubation, and general anesthesia with artificial respiration; remifentanil hydrochloride for Injection for induction of general anesthesia; hydromorphone hydrochloride injection For patients requiring opioid analgesia; nabuphine hydrochloride injection for induction of anesthesia; alfentanil hydrochloride injection for general anesthesia induction; mifepristone preparations for termination of pregnancy or clinical remedial measures used to prevent pregnancy; compound muniziqi granules used to regulate endocrine, enhance immune function, treat liver and gallbladder inflammation, skin diseases, eliminate toxins in the body, etc.; urokinase for Injection for thromboembolic disease; neomycin sulfate API related preparations are used for the prevention and treatment of intestinal diseases in animals, and also used for external prevention and treatment of human skin, eyes, nose, and ears; and progesterone API relevant preparations are used for reactive diagnosis of threatened abortion, habitual abortion, and other amenorrhea or the cause of amenorrhea, etc. It also provides nervous system drugs, steroid hormone drugs, and Uighur ethnic medicines, as well as anti-infection drugs, OTC medicines, and other products.
Humanwell Healthcare (Group) Co.,Ltd. Fundamentals Summary
| 600079 fundamental statistics | |
|---|---|
| Market cap | CN¥36.18b |
| Earnings (TTM) | CN¥1.96b |
| Revenue (TTM) | CN¥25.56b |
18.5x
P/E Ratio1.4x
P/S RatioIs 600079 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600079 income statement (TTM) | |
|---|---|
| Revenue | CN¥25.56b |
| Cost of Revenue | CN¥13.69b |
| Gross Profit | CN¥11.87b |
| Other Expenses | CN¥9.91b |
| Earnings | CN¥1.96b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.22 |
| Gross Margin | 46.44% |
| Net Profit Margin | 7.65% |
| Debt/Equity Ratio | 45.0% |
How did 600079 perform over the long term?
See historical performance and comparison